Current Edition

Abzena

Abzena nabs $65M to bolster manufacturing and research services on both sides of the pond

Roughly one year after dropping designs on a $200 million biologics plant in North Carolina, antibody-drug conjugate specialist Abzena has snared a fresh round of …

Continue Reading →
biologics

Samsung Biologics outlines mRNA ambitions as “Super Plant” speeds toward completion

Samsung Biologics has been on an expansion sprint, with plans to speedily complete a so-called Super Plant already giving way to designs on follow-up facilities …

Continue Reading →
biologics

Merck’s Hilleman Laboratories tees up $58M investment at new Singapore vaccine hub

Singapore has attracted a slate of vaccine heavyweights in recent years. Now, a Merck joint venture is getting in on the action, following in the …

Continue Reading →
biologics

Tianhe Life Sciences leads $9.5m Series A in Clover Biopharma

Tianhe Life Sciences leads $9.5m Series A in Clover Biopharma Clover is utilising its proprietary Trimer-Tag technology platform to develop biologics targeting trimerization-dependent pathways. Clover …

Continue Reading →